Boston-based biotech firm Bambusa Therapeutics (BBTX) successfully upsized and priced its initial public offering at $16.00 per share, the mid-point of its projected range, raising $168.8 million on Thursday, October 29, 2026. The company increased its offering to 10.55 million shares, up from the previously planned 9.38 million. At this pricing, the clinical-stage biotechnology company achieved an initial market capitalization of approximately $815.71 million.
Despite the upsized offering, Bambusa’s stock stumbled during its NASDAQ market debut on Friday, October 30. Opening at $14.88—down $1.12, or 6.25 percent below its IPO price—the stock experienced light trading volume of 292,723 shares. The joint book-runners for the offering included BofA Securities, Evercore ISI, UBS Investment Bank, and Cantor.
Bambusa Therapeutics focuses on developing treatments for Phase 1/2a atopic dermatitis and chronic obstructive pulmonary disease (COPD). The company’s pipeline includes lead product candidates BBT001 and BBT002, alongside preclinical assets targeted at inflammatory bowel diseases and autoantibody-driven autoimmune diseases. According to its prospectus, the company reported a net loss of $48.7 million for the 12-month period ending June 30, 2026.
